BNB Plus Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $811.8K
- Price
- $0.131
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 4.4K
About
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Quick stats
Shares outstanding6.2M
Computed float4.8M
Float / shares78.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000744452
Websitehttps://www.bnbx.io
AI Summary
AI-generated1/10
minormixedother
BNB Plus Corp. Announces Strategic Shift to Institutional Technology Infrastructure for Blockchain and AI; Outlines Plan to Monetize Assets
BNB Plus Corp. (OTCQB: BNBX) announced a strategic shift from a pure BNB Chain digital-asset treasury model to an operating company building institutional infrastructure for blockchain and agentic AI adoption.
The company is evaluating an expanded relationship with GlobalStake Infrastructure LLC, which has been leading its strategic review, and plans to remain active in the BNB Chain ecosystem.
BNBX also intends to evaluate options to monetize its LineaRx subsidiary, whose enzymatic DNA manufacturing platform supplies high-quality DNA for mRNA and other genetic medicines.
Red flags
- Entire announcement is forward-looking with no committed transactions, terms, or financial figures
- Pivot away from digital asset treasury model adds execution risk for a micro-cap
- Potential LineaRx monetization only at evaluation stage; strategic review outcome uncertain
- Tight overlap between company leadership (Shorten) and partner GlobalStake raises governance/conflict questions